Key result
Alirocumab cuts major cardiovascular events ~18% vs. placebo in recent ACS patients with elevated Lp(a).
RCT (n=18,924)
Randomized 1 to 12 months after ACS
Yes
Answers are grounded in this paper and cite their sources.
May support alirocumab in recent ACS with Lp(a) ≥30 mg/dL; leaves open Lp(a)-specific timing of benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2025) conducted an RCT in Recent Acute Coronary Syndrome (n=18,924). Alirocumab vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) in patients with baseline lipoprotein(a) ≥30 mg/dL (HR 0.82, 95% CI 0.74-0.92). Alirocumab reduced the risk of major adverse cardiovascular events by 18% compared to placebo in patients with recent acute coronary syndrome and baseline lipoprotein(a) ≥/dL.
Synapse has enriched 10 related papers. Consider them for comparative context: